Sign In
to Vote &
Create Storyboards.
 
(Cedars-Sinai Medical Center) Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
1
0
0


Storyboard
Print
Share this Article



Comment on this Article

Please Sign In to comment

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard